Tolebrutinib for treating primary progressive multiple sclerosis [ID6574]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 28 July 2025
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis [ID6351]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC